PF-Atlas › Clinical Trials › NCT05120934

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

Amitriptyline 25 MG · Phase 2

Registry ID
NCT05120934
Phase
Phase 2
Status
Recruiting
Drug / intervention
Amitriptyline 25 MG
Sponsor
Mayo Clinic
Start
2021-11-01
Enrollment
25
Locations
1

About this trial

This research study is evaluating the effectiveness of escalating doses of Amitriptyline and Duloxetine in reducing cough frequency in patients with interstitial lung disease (ILD)-related cough.

View NCT05120934 on ClinicalTrials.gov →

Explore related

All Amitriptyline 25 MG trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05120934 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.